Search Results - "Vijan, Vinod"

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease by Nissen, Steven E, Wolski, Kathy, Cho, Leslie, Nicholls, Stephen J, Kastelein, John, Leitersdorf, Eran, Landmesser, Ulf, Blaha, Michael, Lincoff, A Michael, Morishita, Ryuichi, Tsimikas, Sotirios, Liu, Junhao, Manning, Brian, Kozlovski, Plamen, Lesogor, Anastasia, Thuren, Tom, Shibasaki, Taro, Matei, Florin, Silveira, Fábio Serra, Meunch, Andreas, Bada, Aysha, Vijan, Vinod, Bruun, Niels Eske, Nordestgaard, Borge G

“…ObjectiveLipoprotein(a) (Lp(a)) is an important genetically determined risk factor for atherosclerotic vascular disease (ASCVD). With the development of…”
Get full text

Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: Consensus statement IV by Puri, Raman, Bansal, Manish, Mehta, Vimal, Duell, P. Barton, Wong, Nathan D., Iyengar, S.S., Kalra, Dinesh, Nair, Devaki R., Nanda, Navin C., Narula, Jagat, Deedwania, P., Yusuf, Jamal, Dalal, Jamshed J., Shetty, Sadanand, Vijan, Vinod M., Agarwala, Rajeev, Kumar, Soumitra, Vijay, Kris, Khan, Aziz, Wander, Gurpreet Singh, Manoria, P.C., Wangnoo, S.K., Mohan, Viswanathan, Joshi, Shashank R., Singh, Balbir, Kerkar, Prafulla, Rajput, Rajesh, Prabhakar, D., Zargar, Abdul Hamid, Saboo, Banshi, Kasliwal, Ravi R., Ray, Saumitra, Bansal, Sandeep, Rabbani, M.U., Chhabra, Shibba Takkar, Chandra, Sarat, Bardoloi, Neil, Kavalipati, Narasaraju, Sathyamurthy, Immaneni, Mahajan, Kunal, Pradhan, Akshya, Khanna, N.N., Khadgawat, Rajesh, Gupta, Preeti, Chag, Milan C., Gupta, Ashu, Murugnathan, A., Narasingan, S.N., Upadhyaya, Sundeep, Mittal, Vinod, Melinkeri, Rashida Patanwala, Yadav, Madhur, Mubarak, M. Raseed, Pareek, K.K., Dabla, Pradeep Kumar, Nanda, Rashmi, Mohan, J.C.

“…•Indians develop ASCVD about a decade earlier than Western populations.•Subclinical ASCVD reflects the susceptibility to develop adverse CV events.•LAI…”
Get full text

Ultrathin Strut Biodegradable Polymer-Coated Sirolimus-Eluting Coronary Stents: Patient-Level Pooled Analysis From Two Indian Registries by Babu Pothineni, Ramesh, Ajmera, Prakash, Chawla, Kamal Kumar, Mantravadi, Sai Sudhakar, Pathak, Abhijit, Inamdar, Manohar K, Jariwala, Pankaj V, Vijan, Vikrant, Vijan, Vinod, Potdar, Anil

“…Background Despite significant evolution in stent technology, female gender, and patients with diabetes mellitus, multivessel disease, total occlusions, long…”
Get full text

Confronting system barriers for ST- elevation MI in low and middle income countries with a focus on India by Mehta, Sameer, Granger, Christopher, Grines, Cindy Lee, Jacobs, Alice, Henry, Timothy D., Rokos, Ivan, Lansky, Alexandra, Baumbach, Andreas, Botelho, Roberto, Ferre, Alexandra, Yepes, Isaac, Salwan, Roopa, Dalal, Jamshed, Makkar, Jitendra, Bhalla, Neeraj, Mishra, Sundeep, Vijan, Vinod, Hiremath, Shirish

“…Our previous research found seven specific factors that cause system delays in ST-elevation Myocardial infarction management in developing countries. These…”
Get full text

Abstract 4139977: Aggressive LDL cholesterol lowering post ACS with triple combination therapy: Insights from the multicentric LAI-REACT study by Puri, Raman, Mahajan, Kunal, Agarwala, Rajeev, Gupta, Ashu, Batra, Aditya, Khan, Aziz, Vijan, Vinod, Sharma, Jai Bharat, Himral, Surender

“…Abstract only Background: Patients with acute coronary syndrome (ACS) face a high risk of recurrent events in the early post ACS period. Rapid reduction of…”
Get full text

Navigating Cardiovascular Risk and Lipid Management in Indian Patients: Key Messages from the Lipid Association of India 2024 Consensus Statement IV by Puri, Raman, Mehta, Vimal, Bansal, Manish, Shetty, Sadanand, Yusuf, Jamal, Agarwala, Rajeev, Vijan, Vinod Madan, Muruganathan, Arumugam, Tiwaskar, Mangesh, Narasingan, Sanjeevi Nathamuni, Iyengar, Shamanna Seshadri

“…Effective lipid management is crucial for preventing atherosclerotic cardiovascular disease (ASCVD). The Western lipid guidelines may not apply to Indian…”
Get full text

TCT CONNECT-264 Twelve-Month Clinical Outcomes After Implantation of Long Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymers in Atherosclerotic Coronary Lesions by Ajmera, Prakash, Babu, Pothineni Ramesh, Chawla, Kamal Kumar, Mantravadi, Sai Sudhakar, Jariwala, Pankaj, Vijan, Vinod, Vijan, Vikrant, Potdar, Anil, Inamdar, M.K., Pathak, Abhijit

Get full text

TCT CONNECT-238 One Year Clinical Outcomes of Ultrathin Biodegradable Polymer Coated Sirolimus Eluting Stents in Total Occlusion: A Multicenter, All-Comer Analysis by Ajmera, Prakash, Babu, Pothineni Ramesh, Chawla, Kamal Kumar, Mantravadi, Sai Sudhakar, Jariwala, Pankaj, Vijan, Vinod, Vijan, Vikrant, Potdar, Anil, Inamdar, M.K., Pathak, Abhijit

Get full text

Twelve months clinical outcomes of ultrathin strut sirolimus-eluting stent in real-world Indian patients with coronary artery disease by Ajmera, Prakash, Pothineni, Ramesh, Chawla, Kamal Kumar, Mantravadi, Sai Sudhakar, Jariwala, Pankaj, Vijan, Vinod, Vijan, Vikrant

“…PURPOSEAlthough the field of interventional cardiology has witnessed extraordinary progression, the search of an ideal coronary drug-eluting stent is still…”
Get full text

Does Adopting Western Low-density Lipoprotein Cholesterol Targets Expose Indians to a Higher Risk of Cardiovascular Events? Expert Opinion From the Lipid Association of India by Puri, Raman, Mehta, Vimal, Bansal, Manish, Duell, P Barton, Iyengar, S S, Shetty, Sadanand, Graham, Ian, Mohan, J C, Kaul, Upendra, Rao, Dayasagar, Agarwala, Rajeev, Wander, Gurpreet Singh, Hazra, Prakash, Kumar, Soumitra, Wangnoo, S K, Zargar, Abdul Hamid, Saboo, Banshi, Yusuf, Jamal, Vijan, Vinod M, Aggarwal, Prem, Chandra, Sarat, Kasliwal, Ravi R, Manoria, P C, Rabbani, M U, Chag, Milan C, Prabhakar, D, Khan, Aziz, Bordoloi, Neil, Palanippan, Saravanan, Mahajan, Kunal, Pradhan, Akshay, Jain, Dharmender, Murugnathan, A, Dabla, Pradeep Kumar, Desai, Nagaraj, Tiwaskar, Mangesh H, Nair, Devaki R, Singh, Charanjeet, Panda, Jayant, Gupta, Vitull, Sahoo, Prashant, Wong, Nathan D

“…Adverse cardiovascular (CV) events have declined in Western countries due at least in part to aggressive risk factor control, including dyslipidemia…”
Get full text

Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF by Verheugt, Freek W.A., Ambrosio, Giuseppe, Atar, Dan, Bassand, Jean-Pierre, Camm, A. John, Costabel, Juan Pablo, Fitzmaurice, David A., Illingworth, Laura, Goldhaber, Samuel Z., Goto, Shinya, Haas, Sylvia, Jansky, Petr, Kayani, Gloria, Stepinska, Janina, Turpie, Alexander G.G., van Eickels, Martin, Kakkar, Ajay K.

“…Many patients with atrial fibrillation have concomitant coronary artery disease with or without acute coronary syndromes and are in need of additional…”
Get full text

Real-World Use Of Ultrathin-Strut Biodegradable Polymer-Coated Sirolimus-Eluting Stents In Patients With Coronary Artery Disease: 6-Month Clinical Outcomes by Ajmera, Prakash, Pothineni, Ramesh, Chawla, Kamal Kumar, Mantravadi, Sai Sudhakar, Jariwala, Pankaj Vinod, Vijan, Vinod, Vijan, Vikrant

“…Although a number of drug-eluting stents have been developed with different design, composition, and polymers, the search for an ideal drug-eluting stent is…”
Get full text

Rotablation-induced coronary perforation during management of in-stent restenosis by Kaul, U, Singh, B, Vijan, V, Sudan, D, Ghose, T

Get full text